Clinically, CHD4 overexpression is associated with worse outcome in glioblastoma [22], non-small-cell lung cancer (NSCLC) [26], hepatocellular carcinoma [29], rectal cancer [27], triple negative breast cancer [23] and colorectal cancer [24]. The gene discussed is CHD4; the disease is triple-negative breast carcinoma.